AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Geron Corporation
Video analysis: GERN
All videosNo video analysis for this stock yet. Request one from our team.
News: GERN
Geron Sees RYTELO Revenue Near High End of 2026 Guidance as Community Use Expands
Geron NASDAQ: GERN said it expects full-year net revenue from RYTELO to land in the mid-to-high end of its previously stated range, or approximately $230 million to $240 million, as the company continues to expand use of the telomerase inhibitor in lower-risk myelodysplastic syndromes, or MDS.
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, Sept. 2, 2026
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Kuehn Law Encourages Investors of Geron Corporation to Contact Law Firm
NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Geron Corporation (NASDAQ: GERN) breached their fiduciary duties to shareholders.
Geron to Present at Upcoming Investor Conferences
FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that members of the management team are scheduled to participate in the following upcoming investor conferences:
ADAR1 Capital Management LLC Invests $647,000 in Geron Corporation $GERN
ADAR1 Capital Management LLC purchased a new stake in Geron Corporation (NASDAQ: GERN) in the undefined quarter, according to its most recent filing with the SEC. The institutional investor purchased 505,817 shares of the biopharmaceutical company's stock, valued at approximately $647,000. ADAR1 Capital Management LLC owned approximately 0.08% of Geron at the end
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective August 17, 2026, it granted stock options to purchase an aggregate of 311,250 shares of common stock to six newly hired employees as an inducement material to such employees' acceptance of employment with Geron.
Geron Corp: Management's Plan Taking Shape As Competition Heats Up In Myelofibrosis
Genron Corp. reported Q2'26 net product revenues of $57.5M from U.S. sales of Rytelo, up 11% from Q1'26. GERN's management did not increase its 2026 revenue guidance, but did suggest revenues were likely to reach the mid- to high-end of that guidance. A potential competitor in myelofibrosis, KPTI, is looking to file for approval in frontline myelofibrosis, while GERN is running its phase 3 study in relapsed/refractory myelofibrosis.
